Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2190-2196

  Paraskeva, M ^a   Bailey, M ^b   Levvey, B J ^a   Griffiths, A P ^a   Kotsimbos, T C ^a   Williams, T P ^a   Snell, G ^a   Westall, G ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

bronchiolitis obliterans syndrome; cytomegalovirus; Lung transplantation

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TRANSBRONCHIAL BIOPSY; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; BRONCHIOLITIS OBLITERANS; CHILD; CYTOMEGALOVIRUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; VIRUS REPLICATION; YOUNG ADULT;

EID: 80053307064     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03663.x     Document Type: Article

References (28)

1. Estenne M, Maurer JR, Boehler A, et al,. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310. (Pubitemid 34224094)
2. Shilling RA, Wilkes DS,. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009; 9: 1714-1718.
3. Christie JD, Edwards LB, Aurora P, et al,. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28: 1031-1049.
4. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC,. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190: 1076-1083. (Pubitemid 39186793)
5. Chemaly RF, Yen-Lieberman B, Castilla EA, et al,. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004; 42: 2168-2172. (Pubitemid 38637838)
6. Riise GC, Andersson R, Bergstrom T, Lundmark A, Nilsson FN, Olofsson S,. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 2000; 118: 1653-1660. (Pubitemid 32001792)
7. Bauer CC, Jaksch P, Aberle SW, et al,. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007; 45: 324-328.
8. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC,. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75: 2064-2068. (Pubitemid 36793294)
9. Kotsimbos AT, Sinickas V, Glare EM, et al,. Quantitative detection of human cytomegalovirus DNA in lung transplant recipients. Am J Resp Crit Care Med 1997; 156 (Pt 1): 1241-1246.
10. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM,. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Resp Crit Care Med 2010; 181: 1391-1396.
11. Cooper JD, Billingham M, Egan T, et al,. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-716. (Pubitemid 23305066)
12. Limaye AP, Bakthavatsalam R, Kim HW, et al,. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652. (Pubitemid 43948296)
13. Arthurs SK, Eid AJ, Pedersen RA, et al,. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846. (Pubitemid 351417184)
14. Lowance D, Neumayer HH, Legendre CM, et al,. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470. (Pubitemid 29220545)
15. Palmer SM, Limaye AP, Banks M, et al,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
16. Jaksch P, Zweytick B, Kerschner H, et al,. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28: 670-675.
17. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM, 3rd,. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195-202. (Pubitemid 27364208)
18. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR,. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170: 1120-1123. (Pubitemid 39488626)
19. Ettinger NA, Bailey TC, Trulock EP, et al,. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147: 1017-1023. (Pubitemid 23093832)
20. Asberg A, Humar A, Jardine AG, et al,. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213.
21. Duncan AJ, Dummer JS, Paradis IL, et al,. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10 (Pt 1): 638-644; discussion 645-636.
22. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM,. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.
23. Ruttmann E, Geltner C, Bucher B, et al,. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006; 81: 1415-1420. (Pubitemid 43847152)
24. Weigt SS, Elashoff RM, Keane MP, et al,. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8: 1512-1522. (Pubitemid 351989504)
25. Manuel O, Kumar D, Moussa G, et al,. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87: 719-725.
26. Zamora MR,. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4: 1219-1226. (Pubitemid 39013567)
27. Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R,. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18: 179-185. (Pubitemid 38404649)
28. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.